This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Espinel-Ingroff, A. Articles by Rinaldi, M. G. Search for Related Content PubMed PubMed Citation Articles by Espinel-Ingroff, A. Articles by Rinaldi, M. G.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, October 2002, p. 3776-3781, Vol. 40, No. 10
0095-1137/02/$04.00+0     DOI: 10.1128/JCM.40.10.3776-3781.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Optimal Testing Conditions for Determining MICs and Minimum Fungicidal Concentrations of New and Established Antifungal Agents for Uncommon Molds: NCCLS Collaborative Study

Medical College of Virginia Campus of Virginia Commonwealth University, Richmond, Virginia,¹ State of New York Department of Health, Albany, New York,² University of Texas Health Science Center, San Antonio, Texas³

Received 14 May 2002/ Returned for modification 17 June 2002/ Accepted 30 June 2002

This collaborative three-center study evaluated NCCLS M38-A document testing conditions and other testing conditions for the antifungal susceptibility testing of 35 isolates of Aspergillus nidulans, A. terreus, Bipolaris hawaiiensis, B. spicifera, Cladophialophora bantiana, Dactylaria constricta, Fusarium solani, Paecilomyces lilacinus, Scedosporium prolificans, Trichoderma longibrachiatum, and Wangiella dermatitidis for itraconazole, three new triazoles (voriconazole, posaconazole, and ravuconazole), and amphotericin B. MICs and minimum fungicidal concentrations (MFCs) were determined in each center by using four media (standard RPMI-1640 [RPMI], RPMI with 2% dextrose [RPMI-2%], antibiotic medium 3 [M3], and M3 with 2% dextrose [M3-2%]) and two criteria of MIC determination (complete growth inhibition [MICs-0] and prominent growth inhibition [MICs-2]) at 24, 48 and 72 h. MFCs were defined as the lowest drug concentrations that yielded <3 colonies (approximately 99 to 99.5% killing activity). The reproducibility (within three wells) was higher among MICs-0 (93 to 99%) with either RPMI or M3 media than among all MICs-2 (86 to 95%) for the five agents at 48 to 72 h. The agreement for MFCs was lower (86 to 94%). Based on interlaboratory agreement, the optimal testing conditions were RPMI broth, 48 to 72 h of incubation and 100% growth inhibition (MIC-0); MFCs can be obtained after MIC determination with the above optimal testing parameters. These results warrant consideration for inclusion in the future version of the NCCLS M38 document. However, the role of these in vitro values as predictors of clinical outcome remains to be established in clinical trials.

This article has been cited by other articles:

• Lass-Florl, C., Mayr, A., Perkhofer, S., Hinterberger, G., Hausdorfer, J., Speth, C., Fille, M. (2008). Activities of Antifungal Agents against Yeasts and Filamentous Fungi: Assessment according to the Methodology of the European Committee on Antimicrobial Susceptibility Testing. Antimicrob. Agents Chemother. 52: 3637-3641 [Abstract] [Full Text]  
• Troke, P., Aguirrebengoa, K., Arteaga, C., Ellis, D., Heath, C. H., Lutsar, I., Rovira, M., Nguyen, Q., Slavin, M., Chen, S. C. A., on behalf of the Global Scedosporium Study Group, (2008). Treatment of Scedosporiosis with Voriconazole: Clinical Experience with 107 Patients. Antimicrob. Agents Chemother. 52: 1743-1750 [Abstract] [Full Text]  
• Nucci, M., Anaissie, E. (2007). Fusarium Infections in Immunocompromised Patients. Clin. Microbiol. Rev. 20: 695-704 [Abstract] [Full Text]  
• Meletiadis, J., Antachopoulos, C., Stergiopoulou, T., Pournaras, S., Roilides, E., Walsh, T. J. (2007). Differential Fungicidal Activities of Amphotericin B and Voriconazole against Aspergillus Species Determined by Microbroth Methodology. Antimicrob. Agents Chemother. 51: 3329-3337 [Abstract] [Full Text]  
• Espinel-Ingroff, A., Arthington-Skaggs, B., Iqbal, N., Ellis, D., Pfaller, M. A., Messer, S., Rinaldi, M., Fothergill, A., Gibbs, D. L., Wang, A. (2007). Multicenter Evaluation of a New Disk Agar Diffusion Method for Susceptibility Testing of Filamentous Fungi with Voriconazole, Posaconazole, Itraconazole, Amphotericin B, and Caspofungin. J. Clin. Microbiol. 45: 1811-1820 [Abstract] [Full Text]  
• Krishnan, S., Manavathu, E. K., Chandrasekar, P. H. (2005). A comparative study of fungicidal activities of voriconazole and amphotericin B against hyphae of Aspergillus fumigatus. J Antimicrob Chemother 55: 914-920 [Abstract] [Full Text]  
• Lewis, R. E., Wiederhold, N. P., Klepser, M. E. (2005). In Vitro Pharmacodynamics of Amphotericin B, Itraconazole, and Voriconazole against Aspergillus, Fusarium, and Scedosporium spp.. Antimicrob. Agents Chemother. 49: 945-951 [Abstract] [Full Text]  
• Mukherjee, P. K., Sheehan, D. J., Hitchcock, C. A., Ghannoum, M. A. (2005). Combination Treatment of Invasive Fungal Infections. Clin. Microbiol. Rev. 18: 163-194 [Abstract] [Full Text]  
• Ortoneda, M., Capilla, J., Pastor, F. J., Pujol, I., Yustes, C., Serena, C., Guarro, J. (2004). In Vitro Interactions of Approved and Novel Drugs against Paecilomyces spp.. Antimicrob. Agents Chemother. 48: 2727-2729 [Abstract] [Full Text]